IDAP: an integrated literature- and knowledge-graph-driven evidence prioritization pipeline for precision oncology.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 42105215.
- Also identified by DOI 10.1093/bioinformatics/btag300 and PMC identifier 13197120.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Advances in tumor sequencing enable routine detection of dozens to hundreds of somatic alterations per patient, yet only a minority can be linked to established therapeutic evidence. Curated resources such as OncoKB provide high-quality variant-drug annotations but remain limited in coverage, particularly for rare or low-frequency variants. This coverage gap motivates computational frameworks that can integrate curated, literature-derived, graph-based, and clinical-trial evidence to prioritize therapeutic hypotheses for expert review. We developed the Integrated Drug Annotation Pipeline (IDAP), a modular framework that combines four complementary evidence streams: curated variant-drug associations from OncoKB, literature-derived gene-drug mention counts from PubMed abstracts, graph-based drug prioritization using a TxGNN-derived biomedical knowledge graph, and cancer-specific clinical-trial evidence from ClinicalTrials.gov. Given a cancer type and a MAF file, IDAP generates patient-level reports summarizing detected variants, ranked therapeutic hypotheses, supporting evidence layers, and relevant clinical trials. Evaluated across five cancer types (n = 50 samples), IDAP expanded evidence-linked therapeutic hypotheses beyond curated databases alone. Among patients without OncoKB recommendations (26/50), IDAP identified a median of 87 candidate drugs (range: 2-473). To reduce cross-source scale imbalance, the final ranking used within-sample percentile normalization with fixed bonuses for curated evidence, multi-source support, and trial linkage. Under this revised ranking, 24/50 top-ranked candidates were supported by at least two evidence sources and 44/50 had associated ClinicalTrials metadata. In an exploratory external CIViC comparison, IDAP recovered at least one matched CIViC-supported therapy in 28/41 eligible samples, with 13/41 appearing within the top 10 candidates. These outputs are intended to support evidence triage and translational interpretation rather than direct treatment recommendation. IDAP is freely available at https://github.com/joonan-lab/IDAP-pipeline, with full documentation at https://joonan-lab.github.io/IDAP-pipeline. An archived snapshot of the code used in this study is deposited on Zenodo (DOI: https://doi.org/10.5281/zenodo.19301367).
Medical subject headings
- Precision Medicine
- Neoplasms
- Computational Biology
- Medical Oncology
- Software